De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BICO Group Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat BICO Group de winst en omzet met respectievelijk 152.4% en 7.5% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 152.4% per jaar.

Belangrijke informatie

152.4%

Groei van de winst

152.4%

Groei van de winst per aandeel

Life Sciences winstgroei	17.6%
Inkomstengroei	7.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

OTCPK:CLLK.F - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	2,670	-27	-38	146	2
12/31/2024	2,352	-169	-420	-142	2
6/30/2024	2,423	-1,498	-35	98	N/A
3/31/2024	2,426	-1,649	-98	101	N/A
12/31/2023	2,405	-1,697	-113	178	N/A
9/30/2023	2,252	-527	-436	-53	N/A
6/30/2023	2,256	-390	-527	-72	N/A
3/31/2023	2,297	-117	-643	-140	N/A
12/31/2022	2,327	-85	-799	-269	N/A
9/30/2022	2,278	41	-817	-313	N/A
6/30/2022	1,995	-130	-872	-457	N/A
3/31/2022	1,743	-224	-816	-462	N/A
12/31/2021	1,378	-228	-676	-409	N/A
9/30/2021	993	-188	-529	-321	N/A
6/30/2021	744	-96	-328	-150	N/A
3/31/2021	460	-50	-156	-34	N/A
12/31/2020	369	-36	-160	-59	N/A
8/31/2020	236	-62	-154	-72	N/A
5/31/2020	213	-49	-146	-70	N/A
2/29/2020	197	-24	-115	-53	N/A
11/30/2019	173	-5	-73	-31	N/A
8/31/2019	135	1	-52	-16	N/A
5/31/2019	118	3	-59	-16	N/A
2/28/2019	97	4	-38	-2	N/A
11/30/2018	76	2	-34	-12	N/A
8/31/2018	61	1	-31	-12	N/A
5/31/2018	45	1	N/A	-6	N/A
2/28/2018	34	-2	N/A	-7	N/A
11/30/2017	27	-2	N/A	-8	N/A
8/31/2017	20	-1	N/A	-1	N/A
8/31/2016	6	-1	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLLK.F de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLLK.F de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLLK.F de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLLK.F ( 7.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van CLLK.F ( 7.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CLLK.F naar verwachting over 3 jaar hoog zal zijn

BICO Group Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

BICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

BICO Group AB (publ), Annual General Meeting, May 08, 2025

BICO Group AB Announces Management Changes

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven